

Philippe Labrune

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11807086/publications.pdf>

Version: 2024-02-01

55
papers

3,690
citations

172386

29
h-index

155592

55
g-index

56
all docs

56
docs citations

56
times ranked

3335
citing authors

#	ARTICLE	IF	CITATIONS
1	Cellular and metabolic effects of renin-angiotensin system blockade on glycogen storage disease type I nephropathy. <i>Human Molecular Genetics</i> , 2022, 31, 914-928.	1.4	4
2	Disease burden and management of <sc>Criglerâ€Najjar</sc> syndrome: Report of a world registry. <i>Liver International</i> , 2022, 42, 1593-1604.	1.9	8
3	The Glycogen Storage Diseases and Related Disorders. , 2022, , 179-200.		2
4	Puberty and fertility in classic galactosemia. <i>Endocrine Connections</i> , 2021, 10, 240-247.	0.8	6
5	Narrative review of glycogen storage disorder type <sc>III</sc> with a focus on neuromuscular, cardiac and therapeutic aspects. <i>Journal of Inherited Metabolic Disease</i> , 2021, 44, 521-533.	1.7	9
6	Papillary renal cell carcinoma in two young adults with glycogen storage disease type Ia. <i>JIMD Reports</i> , 2020, 52, 17-22.	0.7	2
7	Infectious and digestive complications in glycogen storage disease type Ib: Study of a French cohort. <i>Molecular Genetics and Metabolism Reports</i> , 2020, 23, 100581.	0.4	12
8	Deep morphological analysis of muscle biopsies from type III glycogenesis (GSDIII), debranching enzyme deficiency, revealed stereotyped vacuolar myopathy and autophagy impairment. <i>Acta Neuropathologica Communications</i> , 2019, 7, 167.	2.4	17
9	Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Criglerâ€Najjar Syndrome. <i>Human Gene Therapy</i> , 2019, 30, 1297-1305.	1.4	39
10	Wholeâ€Body Muscle Magnetic Resonance Imaging in Glycogenâ€Storage Disease Type III. <i>Muscle and Nerve</i> , 2019, 60, 72-79.	1.0	6
11	Molecular Classification of Hepatocellular Adenoma Associatesâ€With Risk Factors, Bleeding, and Malignant Transformation. <i>Gastroenterology</i> , 2017, 152, 880-894.e6.	0.6	290
12	Long term longitudinal study of muscle function in patients with glycogen storage disease type IIIa. <i>Molecular Genetics and Metabolism</i> , 2017, 122, 108-116.	0.5	11
13	International clinical guideline for the management of classical galactosemia: diagnosis, treatment, and followâ€up. <i>Journal of Inherited Metabolic Disease</i> , 2017, 40, 171-176.	1.7	132
14	Clinical heterogeneity and phenotype/genotype findings in 5 families with <i>GYG1</i> deficiency. <i>Neurology: Genetics</i> , 2017, 3, e208.	0.9	12
15	Fertility in adult women with classic galactosemia and primary ovarian insufficiency. <i>Fertility and Sterility</i> , 2017, 108, 168-174.	0.5	42
16	Glycogen storage disease type III: diagnosis, genotype, management, clinical course and outcome. <i>Journal of Inherited Metabolic Disease</i> , 2016, 39, 697-704.	1.7	110
17	Progressive development of renal cysts in glycogen storage disease type I. <i>Human Molecular Genetics</i> , 2016, 25, 3784-3797.	1.4	20
18	Cross-sectional retrospective study of muscle function in patients with glycogen storage disease type III. <i>Neuromuscular Disorders</i> , 2016, 26, 584-592.	0.3	13

#	ARTICLE	IF	CITATIONS
19	Peripheral neuropathy in glycogen storage disease type III: Fact or myth?. <i>Muscle and Nerve</i> , 2016, 53, 310-312.	1.0	7
20	No Perinatal HIV-1 Transmission From Women With Effective Antiretroviral Therapy Starting Before Conception. <i>Clinical Infectious Diseases</i> , 2015, 61, civ578.	2.9	180
21	Correction of Hyperbilirubinemia in Gunn Rats by Surgical Delivery of Low Doses of Helper-Dependent Adenoviral Vectors. <i>Human Gene Therapy Methods</i> , 2014, 25, 181-186.	2.1	13
22	Exercise intolerance in Glycogen Storage Disease Type III: Weakness or energy deficiency?. <i>Molecular Genetics and Metabolism</i> , 2013, 109, 14-20.	0.5	38
23	Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I. <i>Journal of Hepatology</i> , 2013, 58, 350-357.	1.8	146
24	Is Intrapartum Intravenous Zidovudine for Prevention of Mother-to-Child HIV-1 Transmission Still Useful in the Combination Antiretroviral Therapy Era?. <i>Clinical Infectious Diseases</i> , 2013, 57, 903-914.	2.9	113
25	GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. <i>Journal of Hepatology</i> , 2012, 56, 184-191.	1.8	354
26	Glucose-6-phosphatase deficiency. <i>Orphanet Journal of Rare Diseases</i> , 2011, 6, 27.	1.2	192
27	Perioperative Management of Hemostasis for Surgery of Benign Hepatic Adenomas in Patients with Glycogen Storage Disease Type Ia. <i>JIMD Reports</i> , 2011, 1, 97-106.	0.7	8
28	Successful Plasmapheresis for Acute and Severe Unconjugated Hyperbilirubinemia in a Child with Crigler Najjar Type I Syndrome. <i>JIMD Reports</i> , 2011, 2, 33-36.	0.7	9
29	Successful Treatment of Severe Cardiomyopathy in Glycogen Storage Disease Type III With D,L-3-Hydroxybutyrate, Ketogenic and High-Protein Diet. <i>Pediatric Research</i> , 2011, 70, 638-641.	1.1	96
30	Lentiviral Vectors That Express UGT1A1 in Liver and Contain miR-142 Target Sequences Normalize Hyperbilirubinemia in Gunn Rats. <i>Gastroenterology</i> , 2010, 139, 999-1007.e2.	0.6	32
31	Investigating glycogenesis type III patients with multi-parametric functional NMR imaging and spectroscopy. <i>Neuromuscular Disorders</i> , 2010, 20, 548-558.	0.3	34
32	KlÄ¼ver Bicy syndrome following hypoglycaemic coma in a patient with glycogen storage disease type Ib. <i>Journal of Inherited Metabolic Disease</i> , 2010, 33, 477-480.	1.7	1
33	The Tunisian population history through the Criglerâ€™Najjar type I syndrome. <i>European Journal of Human Genetics</i> , 2008, 16, 848-853.	1.4	13
34	Successful Pregnancy in a Criglerâ€™Najjar Type I Patient Treated by Phototherapy and Semimonthly Albumin Infusions. <i>Gastroenterology</i> , 2006, 131, 921-924.	0.6	16
35	Further Evidence That the UGT1A1*28 Allele Is Not Associated with Coronary Heart Disease: The ECTIM Study. <i>Clinical Chemistry</i> , 2006, 52, 2313-2314.	1.5	35
36	Paternal isodisomy for chromosome 2 as the cause of Criglerâ€™Najjar type I syndrome. <i>European Journal of Human Genetics</i> , 2005, 13, 278-282.	1.4	35

#	ARTICLE	IF	CITATIONS
37	Increased Levels of Hemostatic Proteins are Independent of Inflammation in Glycogen Storage Disease Type Ia. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2003, 37, 566-570.	0.9	7
38	Crigler-Najjar syndrome type I in Tunisia may be associated with a founder effect related to the Q357R mutation within the UGT1 gene. <i>Human Mutation</i> , 2002, 19, 570-571.	1.1	11
39	Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I). <i>European Journal of Pediatrics</i> , 2002, 161, S20-S34.	1.3	205
40	Glycogen storage disease type I: indications for liver and/or kidney transplantation. <i>European Journal of Pediatrics</i> , 2002, 161, S53-S55.	1.3	39
41	Granulocyte colony-stimulating factor in glycogen storage disease type 1b. Results of the European Study on Glycogen Storage Disease Type 1. <i>European Journal of Pediatrics</i> , 2002, 161, S83-S87.	1.3	68
42	Contraception and pregnancy in women affected by glycogen storage diseases. <i>European Journal of Pediatrics</i> , 2002, 161, S97-S101.	1.3	15
43	Guidelines for management of glycogen storage disease type I - European Study on Glycogen Storage Disease Type I (ESGSD I). <i>European Journal of Pediatrics</i> , 2002, 161, S112-S119.	1.3	89
44	Consensus guidelines for management of glycogen storage disease type 1b - European Study on Glycogen Storage Disease Type 1. <i>European Journal of Pediatrics</i> , 2002, 161, S120-S123.	1.3	55
45	Prenatal diagnosis of Crigler-Najjar syndrome type I by single-strand conformation polymorphism (SSCP). <i>Prenatal Diagnosis</i> , 2002, 22, 914-916.	1.1	13
46	Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European study on glycogen storage disease type I (ESGSD I). <i>European Journal of Pediatrics</i> , 2002, 161, S20-S34.	1.3	233
47	Glycogen storage disease type I: indications for liver and/or kidney transplantation. <i>European Journal of Pediatrics</i> , 2002, 161, S53-S55.	1.3	39
48	Granulocyte colony-stimulating factor in glycogen storage disease type 1b. Results of the European study on glycogen storage disease type 1. <i>European Journal of Pediatrics</i> , 2002, 161, S83-S87.	1.3	55
49	Severe pulmonary arterial hypertension in type 1 glycogen storage disease. <i>European Journal of Pediatrics</i> , 2002, 161, S93-S96.	1.3	30
50	Contraception and pregnancy in women affected by glycogen storage diseases. <i>European Journal of Pediatrics</i> , 2002, 161, S97-S101.	1.3	13
51	Guidelines for management of glycogen storage disease type I – European study on glycogen storage disease type I (ESGSD I). <i>European Journal of Pediatrics</i> , 2002, 161, S112-S119.	1.3	154
52	Consensus guidelines for management of glycogen storage disease type 1b – European study on glycogen storage disease type 1. <i>European Journal of Pediatrics</i> , 2002, 161, S120-S123.	1.3	44
53	Neutropenia, neutrophil dysfunction, and inflammatory bowel disease in glycogen storage disease type Ib: Results of the European Study on Glycogen Storage Disease Type I. <i>Journal of Pediatrics</i> , 2000, 137, 187-191.	0.9	222
54	Hepatocellular Adenomas in Glycogen Storage Disease Type I and III: A Series of 43 Patients and Review of the Literature. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 1997, 24, 276-279.	0.9	272

#	ARTICLE	IF	CITATIONS
55	Genetic heterogeneity of Crigler-Najjar syndrome type I: A study of 14 cases. Human Genetics, 1994, 94, 693-7.	1.8	62